VR Logo

XTL Biopharmaceuticals Ltd. - ADR download report


Healthcare | Biotechnology & Pharma Research

XTL Biopharmaceuticals Ltd. - ADR Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.

IPO Date: 01-Sep-2005

CEO & Director: Mr. Shlomo Spokone Shalev

Chief Financial Officer: Mr. Itay Weinstein

Listing: NASDAQ: XTLB

Country: Israel

Headquarters: Ramat Gan,

Website: https://www.xtlbio.com

Key Facts

Market cap: $8.76 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $0.44 Mln

Cash: $6.13 Mln

Total Debt: $0.00 Mln

Insider's Holding: 18.69%

Liquidity: Low

52 Week range: $1.35 - 6.69

Shares outstanding: 5,449,060

10 Years Aggregate:

  • CFO: $-14.82 Mln
  • EBITDA: $-19.84 Mln
  • Net Profit: $-12.74 Mln

Stock Performance

Time Period XTL Biopharmaceuticals - ADR S&P BSE Sensex S&P Small-Cap 600
YTD-46.21-9.18-18.78
1 month-14.37-4.78-8.00
3 months-37.13-9.66-13.65
1 Year-62.660.81-17.19
3 Years-9.3510.336.10
5 Years-13.9611.345.87
10 Years-26.0811.749.84
As on 01-Jul-2022
Year XTL Biopharmaceuticals - ADR S&P Small-Cap 600 S&P BSE Sensex
2021-8.5825.2721.99
2020121.179.5715.75
2019-20.8120.8614.38
2018-24.25-9.705.87
2017-27.9211.7327.91
2016-54.9924.741.95
2015-28.79-3.36-5.03